[go: up one dir, main page]

AR116053A1 - Anticuerpo monoclonal específico contra el antígeno n del virus respiratorio sincicial humano (vrsh), útiles para el tratamiento de la infección, su detección y diagnóstico - Google Patents

Anticuerpo monoclonal específico contra el antígeno n del virus respiratorio sincicial humano (vrsh), útiles para el tratamiento de la infección, su detección y diagnóstico

Info

Publication number
AR116053A1
AR116053A1 ARP190102496A ARP190102496A AR116053A1 AR 116053 A1 AR116053 A1 AR 116053A1 AR P190102496 A ARP190102496 A AR P190102496A AR P190102496 A ARP190102496 A AR P190102496A AR 116053 A1 AR116053 A1 AR 116053A1
Authority
AR
Argentina
Prior art keywords
rsv
seq
monoclonal antibody
infection
treatment
Prior art date
Application number
ARP190102496A
Other languages
English (en)
Inventor
Ramrez Susan Bueno
Parra Alexis Kalergis
Original Assignee
Univ Pontificia Catolica Chile
Fundacion Copec Univ Catolica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pontificia Catolica Chile, Fundacion Copec Univ Catolica filed Critical Univ Pontificia Catolica Chile
Publication of AR116053A1 publication Critical patent/AR116053A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C07K16/11—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135—Respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere a un anticuerpo monoclonal o fragmento del mismo, que reconoce la proteína N (nucleocápside) del virus respiratorio sincicial humano (VRS), útil para el desarrollo de métodos de diagnóstico de infección por VRS y para la producción de composiciones farmacéuticas destinadas al tratamiento, protección y/o profilaxis de la infección por VRS. Reivindicación 1: Anticuerpo monoclonal o un fragmento de este que se une a la nucleoproteína proteína N del virus respiratorio sincicial humano (VRS) caracterizado porque dicho anticuerpo tiene una región variable de la cadena pesada cuyos CDR1, CDR2 y CDR3 tienen secuencias aminoacídicas con al menos un 97% de identidad con las SEQ ID Nº 5, SEQ ID Nº 6 y SEQ ID Nº 7, respectivamente, y al mismo tiempo tiene una región variable de la cadena liviana cuyos CDR1, CDR2 y CDR3 tienen secuencias aminoacídicas con al menos un 97% de identidad con las SEQ ID Nº 11, SEQ ID Nº 12 y SEQ ID Nº 13, respectivamente. Reivindicación 4: Composición farmacéutica para el tratamiento y/o profilaxis de la infección causada por VRS caracterizada porque comprende el anticuerpo monoclonal o un fragmento de este que se une a la nucleoproteína proteína N de VRS de la reivindicación 1 y un portador farmacéuticamente aceptable. Reivindicación 5: Método de detección de virus respiratorio sincicial humano en una muestra caracterizado porque comprende contactar la muestra con el anticuerpo monoclonal o un fragmento de este que se une a la nucleoproteína proteína N de VRS de la reivindicación 1 y detectar la unión del anticuerpo con el antígeno.
ARP190102496A 2018-09-03 2019-09-02 Anticuerpo monoclonal específico contra el antígeno n del virus respiratorio sincicial humano (vrsh), útiles para el tratamiento de la infección, su detección y diagnóstico AR116053A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CL2018/050079 WO2020047683A1 (es) 2018-09-03 2018-09-03 Anticuerpo monoclonal específico contra el antígeno n del virus respiratorio sincicial humano (vrsh), útiles para el tratamiento de la infección, su detección y diagnóstico

Publications (1)

Publication Number Publication Date
AR116053A1 true AR116053A1 (es) 2021-03-25

Family

ID=69722649

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102496A AR116053A1 (es) 2018-09-03 2019-09-02 Anticuerpo monoclonal específico contra el antígeno n del virus respiratorio sincicial humano (vrsh), útiles para el tratamiento de la infección, su detección y diagnóstico

Country Status (6)

Country Link
US (1) US12065484B2 (es)
EP (1) EP3848389A4 (es)
CN (1) CN112912394B (es)
AR (1) AR116053A1 (es)
CA (1) CA3111336A1 (es)
WO (1) WO2020047683A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113402604B (zh) * 2021-07-14 2022-01-18 河北精硕生物科技有限公司 快速检测病毒的试剂盒及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
DK1340086T3 (da) * 2000-10-17 2008-12-01 Besst Test Aps Assay til direkte detektion af en RS-virusrelateret biologisk celle i en legemsvæskepröve
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
CN101130765B (zh) 2006-08-21 2011-04-06 北京阿斯可来生物工程有限公司 呼吸道合胞病毒检测试剂盒
KR100938998B1 (ko) 2008-01-08 2010-01-28 (주) 에이프로젠 호흡기 신시티움 바이러스에 대한 항체
CL2011003002A1 (es) * 2011-11-25 2012-05-25 Univ Pontificia Catolica Chile Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
CL2014003373A1 (es) * 2014-12-11 2015-04-10 Univ Pontificia Catolica Chile Anticuerpos monoclonales especificos para el antígeno m del virus metapneumovirus humano (hmpv), producidos y secretados por hibridomas celulares , útiles para la deteccion y el diagnostico de la infeccion causada por hmpv.
CL2015002152A1 (es) * 2015-07-31 2016-06-03 Pontificia Universidad Católica De Chile Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnostico de la infección causada por vrsh

Also Published As

Publication number Publication date
WO2020047683A1 (es) 2020-03-12
EP3848389A1 (en) 2021-07-14
CN112912394B (zh) 2024-04-16
CA3111336A1 (en) 2020-03-12
EP3848389A4 (en) 2022-04-13
US20210347862A1 (en) 2021-11-11
CN112912394A (zh) 2021-06-04
US12065484B2 (en) 2024-08-20

Similar Documents

Publication Publication Date Title
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
JP2014506580A5 (es)
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
JP2010521147A5 (es)
RU2014108047A (ru) Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
RU2014143785A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака печени
MX356367B (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
RU2014143784A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
HRP20201345T1 (hr) Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
SI3042917T1 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
AR082149A1 (es) Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
PE20071055A1 (es) Anticuerpos anti mn
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
RU2014146503A (ru) Белки, связывающие антиген - лиганд cd30 человека
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
JP2013501807A5 (es)
PE20221865A1 (es) Anticuerpos contra el virus de la fiebre amarilla y metodos de su generacion y uso
AR099625A1 (es) Anticuerpos de il-21